Phio Pharma Secures New Patent for Photo-aging INTASYL Compound

Phio Pharmaceuticals Corp., a clinical-stage biotechnology company based in Marlborough, Massachusetts, has announced the approval of a new skin care patent in South Korea. The company, listed on NASDAQ under the ticker PHIO, specializes in the development of medical technologies aimed at enhancing the body's immune response to cancer.

Phio's newly approved patent, titled "METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING MMP1," centers around the use of the INTASYL RXI-185 compound. This compound has shown significant potential in treating aging and skin disorders, including photo-aging. RXI-185 works by effectively silencing MMP1 expression in the skin, which helps to slow the breakdown of collagen induced by ultraviolet radiation (UVR). This leads to improvements in skin thickness, elasticity, and the reduction of wrinkles.

The recent patent is part of a broader portfolio that includes 81 issued patents, 77 of which pertain specifically to the INTASYL siRNA gene silencing technology. This technology is notable for its application in various treatments, including those targeting immune checkpoints, cellular differentiation, and metabolic functions for ex vivo cell-based cancer immunotherapies.

Phio Pharmaceuticals' CEO, Robert Bitterman, highlighted the strategic importance of the new patent, stating that it complements their ongoing initiatives in treating skin cancer. He emphasized the robustness and comprehensiveness of Phio's patent portfolio, which is a testament to the company's innovative edge in the field of biotechnology.

Phio’s INTASYL technology represents a unique advancement in RNA interference (RNAi) therapies. Unlike traditional RNAi approaches, INTASYL does not require specialized formulations or drug delivery systems, which simplifies the treatment process. The technology is designed to enhance the efficiency of immune cells in targeting and destroying tumor cells, making it a promising tool in the fight against cancer.

Phio Pharmaceuticals continues to focus on the development of INTASYL-based therapies, which are aimed at specific proteins that inhibit the body's natural cancer-fighting capabilities. The company's proprietary RNAi technology is the only one of its kind that is self-delivering, underscoring Phio’s pioneering role in the field of immuno-oncology therapeutics.

As a clinical-stage company, Phio is actively engaged in various research and development initiatives to bring its innovative therapies from the laboratory to the marketplace. The approval of the RXI-185 patent in South Korea marks a significant milestone in Phio’s global expansion and its mission to address critical healthcare challenges through advanced biotechnology.

In summary, Phio Pharmaceuticals Corp. is making significant strides in the development of cutting-edge medical technologies aimed at enhancing the body's immune response to cancer and treating skin disorders. The recent approval of the INTASYL RXI-185 patent in South Korea not only broadens the company's international footprint but also reinforces its commitment to advancing healthcare through innovative solutions.